385 related articles for article (PubMed ID: 30271116)
1. Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials.
Liu Y; Meng J; Wang G
Drug Des Devel Ther; 2018; 12():3013-3019. PubMed ID: 30271116
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal events with PARP inhibitors in cancer patients: A meta-analysis of phase II/III randomized controlled trials.
Sun W; Li J; Zhang Z; Su X
J Clin Pharm Ther; 2021 Apr; 46(2):241-255. PubMed ID: 33135237
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials.
Hao J; Liu Y; Zhang T; He J; Zhao H; An R; Xue Y
Crit Rev Oncol Hematol; 2021 Jan; 157():103145. PubMed ID: 33254040
[TBL] [Abstract][Full Text] [Related]
4. Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials.
Zhou JX; Feng LJ; Zhang X
Drug Des Devel Ther; 2017; 11():3009-3017. PubMed ID: 29075104
[TBL] [Abstract][Full Text] [Related]
5. Comparison of poly (ADP-ribose) polymerase inhibitors (PARPis) as maintenance therapy for newly-diagnosed and platinum-sensitive recurrent ovarian cancer with
Zhou S; Jiang Y; Luo C; Yuan L
Expert Rev Anticancer Ther; 2024; 24(1-2):59-69. PubMed ID: 38174379
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials.
Shao F; Liu J; Duan Y; Li L; Liu L; Zhang C; He S
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32096544
[TBL] [Abstract][Full Text] [Related]
7. The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis.
Staropoli N; Ciliberto D; Del Giudice T; Iuliano E; Cucè M; Grillone F; Salvino A; Barbieri V; Russo A; Tassone P; Tagliaferri P
Crit Rev Oncol Hematol; 2018 Nov; 131():83-89. PubMed ID: 30293710
[TBL] [Abstract][Full Text] [Related]
8. PARP Inhibitors in Ovarian Cancer.
Mittica G; Ghisoni E; Giannone G; Genta S; Aglietta M; Sapino A; Valabrega G
Recent Pat Anticancer Drug Discov; 2018; 13(4):392-410. PubMed ID: 29512470
[TBL] [Abstract][Full Text] [Related]
9. Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis.
Schettini F; Giudici F; Bernocchi O; Sirico M; Corona SP; Giuliano M; Locci M; Paris I; Scambia G; De Placido S; Rescigno P; Prat A; Curigliano G; Generali D
Eur J Cancer; 2021 May; 149():134-152. PubMed ID: 33862496
[TBL] [Abstract][Full Text] [Related]
10. Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis.
Gong H; Nie D; Huang Y; Li Z
Int J Gynecol Cancer; 2020 Oct; 30(10):1576-1582. PubMed ID: 32817083
[TBL] [Abstract][Full Text] [Related]
11. Comparison of PARPis with Angiogenesis Inhibitors and Chemotherapy for Maintenance in Ovarian Cancer: A Network Meta-Analysis.
Feng Y; Huang H; Wan T; Zhang C; Tong C; Liu J
Adv Ther; 2019 Dec; 36(12):3368-3380. PubMed ID: 31599396
[TBL] [Abstract][Full Text] [Related]
12. Veliparib: a new therapeutic option in ovarian cancer?
Ghisoni E; Giannone G; Tuninetti V; Genta S; Scotto G; Aglietta M; Sangiolo D; Mittica G; Valabrega G
Future Oncol; 2019 Jun; 15(17):1975-1987. PubMed ID: 31074636
[TBL] [Abstract][Full Text] [Related]
13. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Wang L; Wang Q; Xu Y; Cui M; Han L
Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
[TBL] [Abstract][Full Text] [Related]
14. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
15. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
16. Poly(ADP-ribose) polymerase inhibitors as maintenance treatment in patients with newly diagnosed advanced ovarian cancer: a meta-analysis.
Ibrahim EM; Refae AA; Bayer AM; Sagr ER
Future Oncol; 2020 Apr; 16(10):585-596. PubMed ID: 32166978
[No Abstract] [Full Text] [Related]
17. Real-world evidence of poly ADP-ribose polymerase inhibitors in the treatment of ovarian cancer: A systematic literature review.
Borrelli EP; McGladrigan CG
J Oncol Pharm Pract; 2020 Dec; 26(8):1977-1986. PubMed ID: 32659172
[TBL] [Abstract][Full Text] [Related]
18. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
Sheta R; Bachvarova M; Plante M; Renaud MC; Sebastianelli A; Gregoire J; Navarro JM; Perez RB; Masson JY; Bachvarov D
J Transl Med; 2020 Nov; 18(1):439. PubMed ID: 33213473
[TBL] [Abstract][Full Text] [Related]
19. Haematologic toxicities with PARP inhibitors in cancer patients: an up-to-date meta-analysis of 29 randomized controlled trials.
Wang C; Li J
J Clin Pharm Ther; 2021 Jun; 46(3):571-584. PubMed ID: 33421183
[TBL] [Abstract][Full Text] [Related]
20. Risk of fatigue with PARP inhibitors in cancer patients: a systematic review and meta-analysis of 29 phase II/III randomized controlled trials.
Li J; Zhang Z
J Chemother; 2021 Nov; 33(7):452-461. PubMed ID: 33583364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]